Study title: Commentary on the dosage of Buscopan® injection solution in children and juveniles. Boehringer Ingelheim in-house files, May 1995.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Pathological Conditions, Signs and Symptoms | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: HYOSCINE-N-BUTYLBROMIDE | |||||
ATC code: | |||||
Document link: Hyoscine Butylbromide_U96-0263_synopsis.pdf | |||||
Document date: 2011-09-22 | |||||
Study number: U96-0263 | |||||
EudraCT number: | |||||
Scope of study: CLINICAL | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | - |